The pathogenesis of classical Hodgkin lymphoma (cHL) involves environmental and genetic factors. To explore the role of the human leukocyte antigen (HLA) genes, we performed a case-control genotyping study in 338 Dutch cHL patients and more than 5,000 controls using a PCR-based sequence-specific oligonucleotide probe (SSOP) hybridization approach. HLA-A68 and HLA-DR11(5) were significantly increased in the cHL patient population as compared to the controls. Three class II associations were observed in the EBV-cHL population with an increase of HLA-DR15(2) and a decrease of HLA-DR4 and HLA-DR7.
Introduction
Classical Hodgkin lymphoma (cHL) is a typical multi-factorial disease with both environmental and genetic factors acting together to cause disease 1;2 . Epidemiological studies reporting familial clustering of cHL 3 and racial variation in the incidence of cHL 4 give substantial support for an inherited risk to cHL. Genetic associations with specific Human
Leukocyte Antigen (HLA) alleles have been reported in both sporadic and familial cHL 5;6;7 .
Epstein Barr virus (EBV) is a well-established causal factor in a subset of cHL patients 8 . The expression pattern of EBV genes in Hodgkin Reed-Sternberg (HRS) cells is restricted to the two latent membrane proteins (LMP1 and LMP2) and the EBV nuclear antigen 1 (EBNA1) 8 . Despite the lack of immunodominant EBV proteins, LMP and EBNA1-specific T cell responses can be efficiently induced in the context of specific HLA class I or class II molecules [9] [10] [11] . The extreme diversity of HLA genes influences both the affinity and specificity of antigenic peptide binding and is responsible for variations in host anti-viral immune defenses. Genetic variation in host anti-viral immune responses related to HLA polymorphisms might be an important contributor to the development of virally induced malignancies.
Initial HLA association studies in cHL were performed without taking EBV status into account and associations of HLA-A1, HLA-B5, HLA-B8 and HLA-B18 with cHL have been described, although the degree of reproducibility has been low 6;12-14 . More recently, we focused on the EBV+ cHL subgroup in a genetic screening study of the entire HLA region. In a subsequent finescreening analysis we found a strong association of specific HLA-A alleles with susceptibility to EBV+ cHL in Dutch and English patients 5, 15 . HLA-A1 was associated with an increased risk for EBV+ cHL, whereas the HLA-A2 was associated with a decreased risk for EBV+ cHL 16 . This association was confirmed in 934 Scandinavian and English cHL patients in a study by Hjalgrim et al 17 .
In a recently performed genome wide association study (GWAS) in cHL patients, the most significantly associated SNP (rs6903608) was located within the HLA class II region 18 .
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In the present study, we performed an extensive screening of the HLA class I and II genes to investigate possible associations of HLA alleles in the total, the EBV+, and the EBV-cHL (sub)populations. Furthermore, we intended to establish whether specific single nucleotide polymorphism (SNP) positions in the HLA genes that might be shared by multiple HLA alleles are responsible for the observed genetic associations rather than specific HLA alleles.
Materials and methods

Patients and controls
183 cHL patients from the northern region of the Netherlands who participated in the previous population-based genotyping study 5 were included in the present study. 155
additional patients diagnosed and/or treated between 2000 and 2010 at the University Medical Center Groningen in the northern region of the Netherlands were also included. Data on gender, age, and histopathological diagnosis was available for all these patients. No data were available on family history. Classification according to the WHO was performed consistently with the previous study and cHL cases that could not be unequivocally subtyped (usually because of little tissue) were classified as cHL not otherwise specified (NOS) ( Table   1 ). The presence of EBV in tumor cells was detected in formalin fixed paraffin embedded tissue sections by in-situ hybridization (ISH) with a fluorescin-conjugated PNA probe specific for the EBV-encoded EBER RNAs (DAKO, Glostrup, Denmark). The control group consisted of blood bank donors from the same geographical region typed for HLA-A (n=7,099), HLA-B (n=7,283) and HLA-DR (n=5,922) by serological methods and in case of unclear results or apparent class II homozygosity additionally by DNA based methods. All patients gave written informed consent in accordance with the Declaration of Helsinki and the protocols were approved by the medical ethics board of the University Medical Center, Groningen.
HLA genotyping
Blood samples of cHL patients were collected and genomic DNA was extracted from the peripheral blood mononuclear cell pellets using standard laboratory protocols. The HLA genotype was analyzed at medium resolution by a polymerase chain reaction-based sequence-specific oligonucleotide probe hybridization (PCR-SSOP) approach using commercial kits (Gen-Probe, San Diego, CA) and Luminex xMAP technology (Luminex Corp., Austin, TX). The assays were performed according to the manufacturer's instruction in a European Federation for Immunogenetics accredited laboratory. Briefly, biotin-labeled amplification products were generated for exon 2 (for HLA-DRB, HLA-DPB1) and exon 3 (for HLA-A, HLA-B, HLA-Cw and HLA-DQB1) of the HLA genes, followed by a hybridization reaction with a series of SSOPs. Of the 401 PCR-SSOP probes 43 were either positive or negative for all samples and were therefore excluded from the analyses. 
Haplotype analyses of rs6903608 and HLA typings
Our patient cohort was used in the replication series of the recently published GWAS that identified the HLA class II SNP rs6903608 as a highly significant susceptibility marker for cHL 18 . We now compared the SNP alleles (C and T) with the HLA typing data to investigate their linkage. Combined HLA typing and SNP data were available for 278 cHL patients. Twomarker haplotypes of the SNP rs6903608 and the HLA typing were constructed per gene using PHASE v2.1 22, 23 . Allele frequencies of HLA-A, HLA-B and HLA-DR of the total cHL group, the EBV+ subgroup and the EBV-subgroup were compared with allele frequencies of the controls and significant differences were assessed by Chi-square tests. Allele frequencies for HLA-C, HLA-DP and HLA-DQ of the controls were not available. Significant differences in allele frequencies between EBV+ and EBV-cHL patients were also assessed by Chi-square tests.
Statistical analysis
Alleles with a frequency <1% in our population were excluded for all these analyses.
For each phenotype and PCR-SSOP a test was performed, hence a correction for multiple testing was required. Because LD exists between the PCR-SSOPs and between the HLA phenotypes, and because the HLA-phenotypes are derived from the PCR-SSOPs, a
Bonferroni test for 401 PCR-SSOPs and 74 phenotypes would be too conservative.
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Frequencies of HLA typing among haplotypes with a C allele and a T allele at rs6903608 were compared per HLA typing using a Student's t-test.
Results
Clinicopathological characteristics
Characteristics of the patient population in terms of age, gender and histopathological subtype in relation to EBV status is summarized in Table 1 . EBV was present in the tumor cells in 78 (25%) of the 311 cHL patients (for 27 patients EBV status was unknown). In the total group, median age at diagnosis was 35 years (range 13 to 81) and the percentage of males was 52%. Age at time of diagnosis was similar in the EBV+ and EBV-group, i.e. 37
(range 17 to 70) in EBV+ and 32 (range 13 to 81) in EBV-. 43 of 338 cHL patients could not be subtyped and were designated cHL NOS. In the remaining patients, nodular sclerosis (NS) was the most common subtype accounting for 87%. Mixed cellularity (MC) and lymphocyte rich (LR) subtypes were less common with frequencies of 10% and 3%, respectively. The lymphocyte depletion (LD) subtype was absent in this patient group. These characteristics are largely consistent with those published for Caucasian cHL populations.
Allele frequency differences compared to controls
An overview of all allele frequency data, odds ratios and p-values is given in supplementary In the cHL patient group the allele frequency of HLA-A68(28), HLA-DR11(5) and HLA-DR15(2) was significantly increased as compared to the controls (5.0% vs 0.9%; p<10 -10 , For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From 12% vs 0.7%; p<10 -10 , and 21% vs 14%; p=9.8x10 -7 , respectively). In contrast, HLA-DR4 and HLA-DR7 allele frequencies were significantly decreased (13% vs 18%; p=3.1x10 -4 , and 5.2% vs 11%; p=1.4x10 -6 respectively) ( Table 2 ; Figure 1 ).
In EBV-cHL patients a significantly decreased allele frequency was found for HLA-DR4 and HLA-DR7 (12% vs 18%; p=6.3x10 -4 , 5.6% vs 11%; p=1.9x10 -4 ) as compared to the controls and a significantly increased frequency for HLA-A68(28), HLA-DR11(5) and HLA-DR15(2) compared to controls (5.6% vs 0.9%; p<10 -10 , 13% vs 0.7%; p<10 -10 , 23% vs 14%;
p=8.4x10 -7 ) ( Table 3 , figure 1 ).
For the EBV+ cHL subgroup strong associations were observed for HLA-A1, HLA-A2, HLA-A68(28), HLA-B37, HLA-DR10 and HLA-DR11(5) ( Table 3 ; Figure 1 ). The HLA-A1 frequency was increased compared to the controls (33% vs 19%; p=4.6x10 -6 ), whereas the HLA-A2 frequency was decreased (16% vs 34%; p=2.3x10 -6 ) in EBV+ cHL. For HLA-A68(28) (3.2 vs 0.9; p=2.1x10 -3 ), HLA-B37 (8.4% vs 1.9%; p=6.3x10 -9 ) and HLA-DR10 (3.8% vs 1.0%;
p=4.7x10 -4 ) an increased frequency was observed in the EBV+ cHL patients as compared to the controls. For HLA-DR11(5) the allele frequency was increased in the EBV+ cHL population as compared to the controls (4.5% vs 0.7%; p=1.3x10 -7 ).
Differences in HLA allele frequencies between EBV+ and EBV-cHL patients
Comparison of the HLA allele frequencies revealed four significant differences between the EBV+ and EBV-cHL subgroups (Supplementary 
Association analysis of individual PCR-SSOPs in EBV+ and EBV-cHL patients
Analysis of each of the 358 PCR-SSOPs revealed a significant difference between EBV-and EBV+ cHL patients for 19 HLA-A gene PCR-SSOPs (Figure 2 ; Supplemental Table) . Ten of the PCR-SSOPs were specific for the HLA-A*01 allele and were more common in EBV+ cHL patients, while the other nine PCR-SSOPs specific for the HLA-A*02 allele were less common in this patient group (Table 2) . Interestingly the most significant SSOP (C295) is not strongly correlated with any of the other SSOPs (r (Supplemental Figure 1) . This implies that the association of C331 is likely caused by LD with C295. These primers were the only ones that were specific for A*023 and A*024 next to HLA-A*01. In addition, we observed a second independent association for the SSOPs C395
and C211, which were specific for HLA-A*03 and HLA-A*11. A third independent association was shown for the SSOPs C378, C325, C375, C281 and C215. Specificity of these SSOPs is The 19 SSOPs with significant differences contained polymorphic residues within eight of the HLA-A*02-specific and ten of the HLA-A*01 specific SSOPs that are located at key positions in the peptide binding pockets of the HLA molecules 18 (Table 5 ). PCR-SSOPs that were less specific for the HLA-A*01 or HLA-A*02 alleles showed a similar trend in the odds ratio as the significant PCR-SSOPs but with lower p-values (supplementary Table) . 
Association of rs6903608 alleles with HLA alleles
Association of the rs6903608 alleles with the HLA typing revealed 16 significant associations (Table 6 and supplementary Table) . Five of these associations were in agreement with the HLA allele frequency results, i.e. HLA-A1, HLA-DR4, HLA-DR7, HLA-DR11(5) and HLA-DR15(2). The T allele was significantly associated with HLA-A1, HLA-DR4 and HLA-DR7 alleles (28% vs 13%, p= 8.86x10 -6 , 28% vs 0%, p=0 and 9% vs 0%, p=5.89x10 -8 ). The C allele was significantly associated with HLA-DR11 and HLA-DR15 (24% vs 1%, p=8.88x10 -16 and 47% vs 1%, p=0). Six SNP / HLA allele associations, i.e. HLA-B7, HLA-B8, HLA-Cw15, HLA-DR1, HLA-DR3 and HLA-DR8, were not significantly associated with cHL in the HLA allele frequency analysis. The five SNP / HLA-DQB associations have not been analyzed in the HLA allele frequency association analysis due to lack of data from the control population.
Discussion
Inherited variations within the HLA genes as well as variations in host immune responses have long been recognized to be associated with susceptibility to disease, including cHL 25 . A number of HLA genes, alleles and serotypes have previously been reported to be involved in the pathogenesis of cHL 5;6;7 and a recent GWAS indicated the most significant association for cHL to be within the HLA locus 18 . In this study we observed multiple associations that are specific for the EBV+, the EBV-or the total cHL subpopulations. HLA-A68(28) and HLA-DR11(5) are risk alleles for cHL irrespective of the EBV status. HLA-DR4 and HLA-DR7 are associated with decreased susceptibility and HLA-DR15(2) with an increased susceptibility in the EBV-cHL groups. In the EBV+ cHL population an increased susceptibility was observed for HLA-A1, HLA-B37 and HLA-DR10, whereas resistance to disease development was observed for HLA-A2.
For
GWAS indicated that SNP rs6903608 was strongly associated with cHL 18 . To explore associations of the T and C allele with certain HLA alleles, we compared the SNP data of our cohort to the HLA typing data and observed a significant LD for ten HLA alleles (Table 6 ).
Five of the 16 HLA alleles, HLA-A1, HLA-DR4, HLA-DR7, HLA-DR11(5) and HLA-DR15(2),
were also significantly associated with cHL in both the HLA allele and phenotype frequency analysis. HLA-A1 and HLA-DR15 were specifically associated with EBV+ cHL, whereas HLA-DR4 and HLA-DR7 were associated with EBV-cHL and HLA-DR11 with both EBV-and The strong LD observed in the HLA region might affect the results of our HLA association studies. The HLA-A1 antigen is known to be in strong LD with HLA-B8 and in contrast to HLA-A1, HLA-B8 is capable of presenting EBV-derived peptides 30 . We observed that in the EBV+ cHL population 53% (23/43) of the HLA-A1 positive patients also possessed the HLA-B8 allele, whereas in the EBV-cHL population this percentage was 66% (46/70). In theory, presence of HLA-B8 in HLA-A1 carrying EBV+ cHL, might overcome the less effective presentation of EBV derived peptides by HLA-A1. Nevertheless we found a very significant effect for HLA-A1 in this study consistent with previous studies 5;15;16 and no significant differences for HLA-B8.
The predisposing effects of HLA-B37 and HLA-DR10 for EBV+ cHL might at least be partly attributed to their strong LD with HLA-A1 since HLA-A1-B37-Cw6-DR10-DQ5 is a rather common haplotype in the Caucasian population. In our study, 13 of 14 HLA-B37+ and five of six HLA-DR10+ EBV+ cHL patients also carried HLA-A1. Although we do not have haplotype data available, seven patients were found to potentially possess the HLA-A1-B37-DR10 haplotype, in which five were EBV+.
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Republic, Sweden, Denmark, and United States. Distribution of HLA alleles varies widely by ethnicity and geography, which might lead to differences in disease-associated HLA alleles among different ethnic groups and geographic locations. In addition most case-control studies used low-resolution serological HLA typing. A limitation of this approach is the inability to discriminate between specific allele variants, which might be more or less common in different populations.
The HLA-DR4, HLA-DR7 and HLA-DR15(2) class II associations were not observed in the EBV+ subgroup and represent associations specific for the EBV-cHL subgroup. An association with DRB1*15:01 has been reported previously to be associated with familial NS subtype cHL 7 . HLA-DR15(2) is the serological name for the HLA-DRB1-15:01 typing and this association is thus similar to the association that we found to be specific for EBV-cHL.
The HLA-A1 and HLA-A2 class I associations were specific for the EBV+ cHL subgroup, whereas the HLA class II associations were most pronounced in the EBV-cHL subgroup. HLA class II molecules present exogenous antigenic peptides to CD4+ helper T cells, whereas HLA class I molecules bind and present peptides derived from endogenous proteins to CD8+ cytotoxic T lymphocytes 32 . Our findings thus support a differential immunogenic basis with a more prominent role in the effector phase of the immune response for HLA class I in EBV+ cHL and an immunoregulatory role for HLA class II in the For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From pathogenesis of EBV-cHL. This suggests presence of a specific HLA class II restricted antigen involved in the pathogenesis of EBV-cHL. Whether this is a pathogen-derived antigen or an antigen derived from a mutated protein remains unknown.
In conclusion, the current study confirms the previously reported genetic association of the HLA-A1 and HLA-A2 in EBV+ cHL. The genetic influence of these two HLA antigens is more important than individual SNPs that might be shared by multiple HLA-A alleles. In addition, we demonstrated two significant associations (HLA-A68 and HLA-DR11 (5) All authors supervised writing of the manuscript.
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